Sivik Global Healthcare LLC Invests $2.98 Million in Edwards Lifesciences Corporation $EW

Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 35,000 shares of the medical research company’s stock, valued at approximately $2,984,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences during the third quarter valued at $25,000. True Wealth Design LLC lifted its holdings in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. Finally, Dorato Capital Management purchased a new position in Edwards Lifesciences during the fourth quarter valued at $29,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total transaction of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the sale, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 74,077 shares of company stock worth $6,165,444. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Barclays reaffirmed an “overweight” rating and set a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. UBS Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Finally, TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Stock Performance

NYSE EW opened at $80.80 on Wednesday. The stock’s fifty day moving average is $81.53 and its two-hundred day moving average is $81.93. The firm has a market capitalization of $46.59 billion, a P/E ratio of 44.16, a price-to-earnings-growth ratio of 2.11 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.